INVA Q2 2025 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$100M-3.0% YoY

Gross Profit

$90M89.4% margin

Operating Income

-$49M-48.6% margin

Net Income

$64M63.5% margin

EPS (Diluted)

$0.77

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$619M

Stockholders' Equity

$715M

Cash & Equivalents

$398M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$103M	-3.0%
Gross Profit	$90M	$85M	+5.6%
Operating Income	-$49M	$55M	-189.1%
Net Income	$64M	-$35M	+283.6%

Revenue Segments

Royalty

$64M64%

Product

$35M35%

License And Other Revenue

$910,0001%